LUNG vs. NPCE, CERS, ANIK, TCMD, SRDX, LYRA, GUTS, RCEL, NYXH, and BVS
Should you be buying Pulmonx stock or one of its competitors? The main competitors of Pulmonx include NeuroPace (NPCE), Cerus (CERS), Anika Therapeutics (ANIK), Tactile Systems Technology (TCMD), Surmodics (SRDX), Lyra Therapeutics (LYRA), Fractyl Health (GUTS), AVITA Medical (RCEL), Nyxoah (NYXH), and Bioventus (BVS). These companies are all part of the "surgical & medical instruments" industry.
NeuroPace (NASDAQ:NPCE) and Pulmonx (NASDAQ:LUNG) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, community ranking, profitability and dividends.
NeuroPace currently has a consensus target price of $15.67, suggesting a potential upside of 14.94%. Pulmonx has a consensus target price of $15.83, suggesting a potential upside of 73.80%. Given NeuroPace's higher possible upside, analysts clearly believe Pulmonx is more favorable than NeuroPace.
NeuroPace has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500. Comparatively, Pulmonx has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500.
NeuroPace has a net margin of -50.38% compared to NeuroPace's net margin of -88.60%. NeuroPace's return on equity of -46.63% beat Pulmonx's return on equity.
NeuroPace has higher earnings, but lower revenue than Pulmonx. NeuroPace is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.
78.8% of NeuroPace shares are owned by institutional investors. Comparatively, 91.0% of Pulmonx shares are owned by institutional investors. 27.5% of NeuroPace shares are owned by insiders. Comparatively, 5.7% of Pulmonx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Pulmonx received 5 more outperform votes than NeuroPace when rated by MarketBeat users. However, 54.76% of users gave NeuroPace an outperform vote while only 41.79% of users gave Pulmonx an outperform vote.
In the previous week, Pulmonx had 3 more articles in the media than NeuroPace. MarketBeat recorded 6 mentions for Pulmonx and 3 mentions for NeuroPace. Pulmonx's average media sentiment score of 0.78 beat NeuroPace's score of 0.71 indicating that NeuroPace is being referred to more favorably in the media.
Summary
NeuroPace beats Pulmonx on 11 of the 18 factors compared between the two stocks.
Get Pulmonx News Delivered to You Automatically
Sign up to receive the latest news and ratings for LUNG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LUNG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools